Stock Upgrades Today See Wall Street Boost Confidence

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  18 Nov 2025
 

•   AEP  
   
  -0.12%
•   AIRO  
   
  -0.20%
•   AKAM  
   
  -0.39%
•   ALKS  
   
  -0.07%
•   AMD  
   
  -0.40%

$AEP American Electric Power gained attention after Jefferies upgraded its outlook from Hold to Buy. The firm sees modest upside potential of 4.15%, citing steady utility cash flows and a resilient energy demand profile that positions AEP as a stable addition to any portfolio.

$AIRO AIRO Group Holdings continues to impress as Mizuho maintained an Outperform rating. Analysts foresee explosive upside potential of 183.47%, driven by the innovative initiatives and growth prospects in niche markets, making it a compelling speculative play for aggressive traders.

$AKAM Akamai Technologies entered the spotlight with Oppenheimer initiating coverage at Outperform. Analysts project a 12.24% upside, highlighting its strong cybersecurity and content delivery infrastructure as key growth drivers in a digital-first world.

$ALKS Alkermes remains attractive with Truist Securities reaffirming a Buy recommendation and forecasting 51.50% upside. Analysts emphasize the potential in the neuroscience and specialty pharma pipeline as a catalyst for mid-term growth.

$AMD Advanced Micro Devices maintains its momentum with Melius Research holding a Buy rating and raising the price target to $380. With multi-year growth visibility and its strong positioning in AI and high-performance computing, AMD continues to capture investor attention.

$APOG Apogee Enterprises saw DA Davidson upgrade coverage from Neutral to Buy, with a projected upside of 55.10%. The focus on sustainable building solutions and innovative glass products makes it a standout in the industrial materials sector.

$AXON Axon Enterprise received an Outperform initiation from RBC Capital with a 51.06% upside. Analysts highlight Axon dominance in law enforcement technology and expanding digital evidence solutions as key drivers for long-term growth.

$GOOG Alphabet caught traders’ eyes as Loop Capital upgraded the stock amid AI optimism. Analysts forecast a 19% upside, citing robust search revenue and AI integration as catalysts that could sustain momentum in the coming quarters.

$HOTH Hoth Therapeutics retained a Buy rating from D. Boral Capital, with an astonishing upside of 242.86%. The innovative therapeutic pipeline in biotech offers speculative growth potential for investors seeking outsized returns.

$LLY Eli Lilly continues to be a favorite with TD Cowen maintaining a Buy rating and a $960 price target. The strong pipeline and government partnerships support near-term growth and make LLY a defensive growth play.

$MRVL Marvell Technology reaffirmed a Buy with a $120 price target. Analysts point to strong semiconductor demand and growth in networking and AI-related chips as drivers for its projected upside.

$OKTA Okta maintained an Outperform rating from Mizuho, signaling a 49.72% potential upside. As identity management and cybersecurity become increasingly vital, Okta is well-positioned to capture market share in the fast-growing security sector.

$OSTX OS Therapies remains one of the most speculative yet enticing opportunities, with D. Boral Capital projecting a massive 675.44% upside. Investors are watching its clinical pipeline closely, making it a high-risk, high-reward pick.

$PIII P3 Health Partners received a Buy from Lake Street with a projected upside of 121.74%. Analysts highlight its rapid expansion in healthcare services as a key growth engine driving long-term potential.

$STGW Stagwell gained attention after Seaport Global initiated coverage with a Buy recommendation and a 67.46% upside. The digital marketing and communications strategy is expected to benefit from increased brand demand and media growth.

$VSAT Viasat remains a strategic pick following contract renewals with NEXCOM, supporting global managed connectivity services. The defense and commercial communications projects reinforce long-term stability and growth potential.

$VVOS Vivos Therapeutics was initiated at Buy by HC Wainwright with a 121.28% upside. Its innovative biotech solutions and robust early-stage pipeline provide compelling opportunities for growth-minded investors.

View All Headlines